# Doxycycline to Protect Heart Muscle After Heart Attacks

Study · id `cardio:ct-nct03508232` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03508232](<https://clinicaltrials.gov/study/NCT03508232>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03508232

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Heart failure; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 174 participants.

## Technical summary

Registry record NCT03508232. Randomized; quadruple masking; primary purpose prevention. Start 2020-01-06 (actual); primary completion 2025-07-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 174 participants (enrolled count; ClinicalTrials.gov record NCT03508232, source copy `cardio:ctgov-nct03508232-2026-04-13`, retrieved 2026-10-26)
- Started: 2020-01-06 (actual) (ClinicalTrials.gov record NCT03508232, source copy `cardio:ctgov-nct03508232-2026-04-13`, retrieved 2026-10-26)
- Primary completion: 2025-07-26 (actual) (ClinicalTrials.gov record NCT03508232, source copy `cardio:ctgov-nct03508232-2026-04-13`, retrieved 2026-10-26)
- Completion: 2025-08-26 (actual) (ClinicalTrials.gov record NCT03508232, source copy `cardio:ctgov-nct03508232-2026-04-13`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT03508232, source copy `cardio:ctgov-nct03508232-2026-04-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03508232-2026-04-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Doxycycline to Protect Heart Muscle After Heart Attacks
- Condition: ST Segment Elevation Myocardial Infarction
- Condition: Heart Failure
- Intervention (Drug): Placebo
- Intervention (Drug): Doxycycline Hyclate
- Lead sponsor: University of Alberta
- Lead sponsor class: OTHER
- Collaborator: Royal Alexandra Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: University of Alberta (`cardio:org-university-of-alberta`)

## Provenance

Content hash: d5b89318c166e0f758be2b9988122bda556862f1bf91c7e41bd658fac074234b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
